

ACS NLCRT Lung Cancer Biomarker Testing ECHO Year 3

Post Session 4: Recap & Resources

This document compiles some of the key resources mentioned during **Session 4: Improving Turnaround Time**. To review all publications, articles, or commentaries mentioned, we recommend reviewing the presentation recording and PowerPoint presentation.

All slides and recordings can be found [here](#).

CASE PRESENTATION SUMMARY & FEEDBACK

HIGHLIGHTS OF SESSION RESOURCES

- CMS “14-Day Rule” <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Lab-DOS-Policy>
- Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice [Link](#)
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer [Link](#)

Practice guidelines:

- IASLC Global Molecular Database for Thoracic Malignancies: Call for Data [Link](#)
- Molecular testing guidelines for treatment with targeted Tyrosine Kinase Inhibitors [Link](#)
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023 [Link](#)
- Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline [Link](#)

Other:

- Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists [Link](#)
- Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer [Link](#)
- Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients [Link](#)

TOOLS/RESOURCES OF POTENTIAL INTEREST

- **GO₂ For Lung Cancer Patient Education Materials:** Biomarker Testing [Link](#) ; Targeted Therapy [Link](#); Immunotherapy [Link](#)
- Free CME/CNE - Interpreting cancer biomarker testing - When is additional testing needed? (jax.org) [Link](#)